Gastrointestinal Stromal Tumor (GIST) Treatment Gastrointestinal stromal tumors (GISTs) are rare tumors arising from the digestive tract, most commonly in the stomach or small intestine. Treatment strategies depend on factors such as tumor size, location, mutation type, and metastasis status. ### **Surgical Treatment** For localized GISTs, surgery is the primary treatment. Complete resection with negative margins is the goal, avoiding tumor rupture to prevent recurrence. Lymph node removal is usually unnecessary, as GISTs rarely spread via lymphatics. ### **Targeted Therapy** GISTs are driven by mutations in the *KIT* or *PDGFRA* genes, making targeted therapy crucial. - **Imatinib (Gleevec)**: A tyrosine kinase inhibitor (TKI) and first-line treatment for metastatic or unresectable GIST. It is also used as adjuvant therapy post-surgery for high-risk patients. - **Sunitinib (Sutent)**: A second-line treatment for imatinib-resistant or intolerant cases. - **Regorafenib (Stivarga)**: Used for patients who fail imatinib and sunitinib. - **Ripretinib (Qinlock)**: A fourth-line treatment for advanced GIST. ### **Adjuvant and Neoadjuvant Therapy** Adjuvant imatinib is given post-surgery for high-risk recurrence cases. Neoadjuvant imatinib may shrink large tumors before surgery, preserving organ function. ### **Emerging Therapies** Ongoing research explores novel TKIs, immunotherapy, and combination therapies to overcome resistance and improve outcomes. ### **Monitoring and Follow-Up** Regular imaging (CT or MRI) is needed to detect recurrence or progression. Long-term imatinib use is often necessary for metastatic cases. ### **Conclusion** Advancements in targeted therapy have transformed GIST treatment, improving survival rates. Personalized approaches based on mutation status remain essential for optimal care. Consult us today.👇 Contact Us📞 +91 7303055137 Email:care.cure.clinic.2020@gmail.com